SIO News

 


November 20, 2020


 


.NEWS FROM SIO

Register Now for SIO 2021!


Have you heard? Registration for the SIO2021 Annual Scientific Meeting is now open! The premier IO event, taking place virtually 3–6 February 2021, is now easier than ever to attend — regardless of your location.

Take a look at the preliminary program to see what you can expect at the virtual experience.

SIO2021 offers a mix of live and on-demand programming for IO professionals at all stages of their careers, from the advanced education you've come to expect to an increased amount of practical mid-career opportunities.

Our enhanced virtual curriculum is designed to allow any attendee to engage and advance as the meeting progresses!

Plus... Your registration grants you access to all session recordings for two (2) months following this year's virtual meeting — giving you more time to revisit your favorite content offerings, review sessions you may have missed, and earn valuable CME credits.

REGISTER NOW
Share on FacebookTwitterShare on LinkedinE-mail article


SIO Submits Updates to the NCCN Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease
The Society of Interventional Oncology submitted updates to the NCCN Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease. Submitted by Sirish A. Kishore MD, Clinical Assistant Professor of Radiology (Affiliated), Stanford University, Adie Friedman MD, Assistant Professor of Radiology, Mount Sinai Medical Center, and Deepak Sudheendra MD, Assistant Professor of Clinical Radiology, University of Pennsylvania. This Letter requests five specific changes for inclusion to the guidelines for Cancer-Associated Venous Thromboembolic Disease. Download the complete letter here.
Share on FacebookTwitterShare on LinkedinE-mail article

 SPONSORED CONTENT
Promoted by Varian Medical Systems

Time is Running Out to Secure a Spot in SIO's Liver Directed Therapy Master Class!


Only three weeks remain until the Society of Interventional Oncology (SIO) delivers a virtual Master Class on Liver Directed Therapy.

Knock another item off your to-do list before the holidays and secure your spot now—while there's still time! You must register by Monday, 23 November to receive your hands-on materials in time for this interactive event.

This program is supported by an unrestricted education grant by Guerbet

Register Now
Share on FacebookTwitterShare on LinkedinE-mail article

 PRODUCT SHOWCASE
OPuS One Clinical Study News
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.

LEARN MORE

 


.TOP NEWS

Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma
Clinical Journal of Gastroenterology via Springer Link
A 72-year-old man underwent transarterial chemoembolization (TACE) for solitary hepatocellular carcinoma (HCC) located on the S6 segment. He had a history of anti-viral therapy for hepatitis C virus and was being treated for diabetes mellitus with inadequate control. On day 28 after TACE, he visited our hospital again, with complaints of fever and abdominal pain in the right upper quadrant.

READ MORE
Share on FacebookTwitterShare on LinkedinE-mail article

 

Photoactivatable metabolic warheads enable precise and safe ablation of target cells in vivo
ChemRxiv
Photoactivatable molecules enable ablation of malignant cells under the control of light, yet current agents can be ineffective at early stages of disease when target cells are similar to healthy surrounding tissues. In this work, we describe a chemical platform based on amino-substituted benzoselenadiazoles to build photosensitizers that mimic native metabolites as indicators of disease onset and progression.

READ MORE
Share on FacebookTwitterShare on LinkedinE-mail article



 FEATURED ARTICLE

  Pancreatic Cancer Clinical Study Now Enrolling Patients
Promoted by AngioDynamics
DIRECT, a clinical study evaluating the effectiveness of IRE technology on stage III pancreatic cancer, is actively enrolling patients. DIRECT, initiated by AngioDynamics, is led by Co-Principal Investigators – Govindarajan Narayanan, MD, Chief of Interventional Oncology at Miami Cancer Institute and Robert C.G. Martin, MD, PhD, Surgical Oncology at the University of Louisville. Visit AngioDIRECT.com to learn more.

LEARN MORE
 

Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization
Clinical Journal of Gastroenterology via Springer Link
Multidisciplinary treatment is recommended for the management of patients with advanced hepatocellular carcinoma (HCC). Some operative decollateralization of extrahepatic feeding arteries with laparotomy have been introduced for HCC. We herein newly develop laparoscopic devascularization (LDEV) to continue transarterial chemoembolization (TACE) for HCC with extrahepatic collateral arteries.

READ MORE
Share on FacebookTwitterShare on LinkedinE-mail article

PRODUCT SHOWCASE

Bringing AR Guidance to Imaging
Clear Guide Medical brings AR guidance to your interventional procedures, seamlessly fusing CT or MRI with ultrasound for optimized instrument navigation. This new standard of care achieves 2 mm accuracy in procedures such as biopsies and ablations--all while minimizing radiation exposure.
 
LEARN MORE
 
 

Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.

Connect with Highly Defined Buyers and Maximize Your Brand Exposure


 
LEARN MORE
 

Current perspectives on the tumor microenvironment in hepatocellular carcinoma
Hepatology International via Springer Link
Hepatocellular carcinoma (HCC) is a heterogeneous inflammation-driven malignancy, which, despite significant advances in management, continues to portend a poor prognosis. Recent advances in basic and translational research have increasingly defined the role of the tumor microenvironment in the development and progression of HCC and facilitated the development of novel molecular targets.

READ MORE
Share on FacebookTwitterShare on LinkedinE-mail article

 

 
IO Insights
Connect with SIO



Dennis Hall, Director of Publishing, MultiView, 469-420-2656 | Download media kit
Lexi Silverberg, Content Editor, MultiView, 469-420-2609 | Contribute news

The Society of Interventional Oncology
2025 M Street, NW, Suite 800  |  Washington, DC 20036 
202-367-1164  |  Contact Us  |  www.sio-central.org

Click here to unsubscribe. 

Learn how to add us to your safe sender list so our emails get to your inbox.



ASSN PNG LOGO
ADVERTISE

SUBSCRIBE

PAST ISSUES

Published by MultiView

 




7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063